NASDAQ: NRXP
Nrx Pharmaceuticals Inc Stock Ownership - Who owns Nrx Pharmaceuticals?

Insider buying vs selling

Have Nrx Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jonathan C. JavittChairman and Chief Scientist2024-12-1740,000$1.17
$46.80kBuy

1 of 1

NRXP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when NRXP insiders and whales buy or sell their stock.

NRXP Shareholders

What type of owners hold Nrx Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Daniel C. Javitt119.80%23,606,657$66.10MInsider
Jonathan C. Javitt81.12%15,985,163$44.76MInsider
B Group Inc15.22%3,000,000$8.40MInsider
Chaim Hurvitz12.30%2,423,236$6.79MInsider
Brac Lending Group LLC11.31%2,228,435$6.24MInsider
Anson Funds Management LP8.14%1,604,975$4.49MInstitution
Polar Asset Management Partners Inc5.10%1,005,536$2.82MInsider
Big Rock Partners Sponsor LLC2.64%519,315$1.45MInsider
Vanguard Group Inc2.29%452,175$1.27MInstitution
Patrick John Flynn2.05%404,291$1.13MInsider

1 of 3

NRXP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NRXP5.67%94.33%Net Buying
PMVP56.07%43.93%Net SellingNet Selling
GANX10.54%3.63%
CELU2.01%97.99%Net Buying
APLT61.09%8.42%Net Selling

Nrx Pharmaceuticals Stock Ownership FAQ

Who owns Nrx Pharmaceuticals?

Nrx Pharmaceuticals (NASDAQ: NRXP) is owned by 15.20% institutional shareholders, 252.73% Nrx Pharmaceuticals insiders, and 0.00% retail investors. Daniel C. Javitt is the largest individual Nrx Pharmaceuticals shareholder, owning 23.61M shares representing 119.80% of the company. Daniel C. Javitt's Nrx Pharmaceuticals shares are currently valued at $70.82M.

If you're new to stock investing, here's how to buy Nrx Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.